Wedbush Reiterates Outperform Rating for Vigil Neuroscience (NASDAQ:VIGL)

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a note issued to investors on Wednesday, Benzinga reports. They presently have a $22.00 price target on the stock.

A number of other analysts have also commented on VIGL. HC Wainwright reaffirmed a “buy” rating and set a $24.00 target price on shares of Vigil Neuroscience in a report on Wednesday. JMP Securities reaffirmed a “market outperform” rating and set a $23.00 price objective on shares of Vigil Neuroscience in a research note on Thursday, April 18th.

Vigil Neuroscience Stock Down 13.1 %

Vigil Neuroscience stock opened at $3.29 on Wednesday. The business’s 50-day simple moving average is $3.07 and its 200 day simple moving average is $3.69. The stock has a market cap of $123.46 million, a price-to-earnings ratio of -1.54 and a beta of 1.87. Vigil Neuroscience has a 12-month low of $2.50 and a 12-month high of $11.11.

Vigil Neuroscience (NASDAQ:VIGL) last issued its earnings results on Tuesday, March 26th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.01). As a group, sell-side analysts expect that Vigil Neuroscience will post -2.56 EPS for the current year.

Hedge Funds Weigh In On Vigil Neuroscience

An institutional investor recently raised its position in Vigil Neuroscience stock. PEAK6 Investments LLC raised its holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL) by 66.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,796 shares of the company’s stock after acquiring an additional 9,459 shares during the period. PEAK6 Investments LLC owned about 0.07% of Vigil Neuroscience worth $128,000 as of its most recent filing with the Securities and Exchange Commission. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.